Literature DB >> 21346985

Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.

Rave Harpaz1, Krystl Haerian, Herbert S Chase, Carol Friedman.   

Abstract

Many adverse drug effects (ADEs) can be attributed to drug interactions. Spontaneous reporting systems (SRS) provide a rich opportunity to detect novel post-marketed drug interaction adverse effects (DIAEs), as they include populations not well represented in clinical trials. However, their identification in SRS is nontrivial. Most existing research have addressed the statistical issues used to test or verify DIAEs, but not their identification as part of a systematic large scale database-wide mining process as discussed in this work. This paper examines the application of a highly optimized and tailored implementation of the Apriori algorithm, as well as methods addressing data quality issues, to the identification of DIAEs in FDAs SRS.

Entities:  

Mesh:

Year:  2010        PMID: 21346985      PMCID: PMC3041376     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  15 in total

1.  Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole.

Authors:  E P Van Puijenbroek; A C Egberts; R H Meyboom; H G Leufkens
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

2.  Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.

Authors:  Ana Szarfman; Stella G Machado; Robert T O'Neill
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Application of data mining techniques in pharmacovigilance.

Authors:  Andrew M Wilson; Lehana Thabane; Anne Holbrook
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

4.  Automated encoding of clinical documents based on natural language processing.

Authors:  Carol Friedman; Lyudmila Shagina; Yves Lussier; George Hripcsak
Journal:  J Am Med Inform Assoc       Date:  2004-06-07       Impact factor: 4.497

Review 5.  Perspectives on the use of data mining in pharmaco-vigilance.

Authors:  June Almenoff; Joseph M Tonning; A Lawrence Gould; Ana Szarfman; Manfred Hauben; Rita Ouellet-Hellstrom; Robert Ball; Ken Hornbuckle; Louisa Walsh; Chuen Yee; Susan T Sacks; Nancy Yuen; Vaishali Patadia; Michael Blum; Mike Johnston; Charles Gerrits; Harry Seifert; Karol Lacroix
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  The role of data mining in pharmacovigilance.

Authors:  Manfred Hauben; David Madigan; Charles M Gerrits; Louisa Walsh; Eugene P Van Puijenbroek
Journal:  Expert Opin Drug Saf       Date:  2005-09       Impact factor: 4.250

Review 7.  Data mining for signals in spontaneous reporting databases: proceed with caution.

Authors:  Wendy P Stephenson; Manfred Hauben
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

8.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

9.  Mining multi-item drug adverse effect associations in spontaneous reporting systems.

Authors:  Rave Harpaz; Herbert S Chase; Carol Friedman
Journal:  BMC Bioinformatics       Date:  2010-10-28       Impact factor: 3.169

Review 10.  Novel statistical tools for monitoring the safety of marketed drugs.

Authors:  J S Almenoff; E N Pattishall; T G Gibbs; W DuMouchel; S J W Evans; N Yuen
Journal:  Clin Pharmacol Ther       Date:  2007-05-30       Impact factor: 6.875

View more
  22 in total

1.  Predicting adverse drug events from personal health messages.

Authors:  Brant W Chee; Richard Berlin; Bruce Schatz
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

2.  The potential of translational bioinformatics approaches for pharmacology research.

Authors:  Lang Li
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

3.  Predicting Adverse Drug Effects from Literature- and Database-Mined Assertions.

Authors:  Mary K La; Alexander Sedykh; Denis Fourches; Eugene Muratov; Alexander Tropsha
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

4.  The contribution of the vaccine adverse event text mining system to the classification of possible Guillain-Barré syndrome reports.

Authors:  T Botsis; E J Woo; R Ball
Journal:  Appl Clin Inform       Date:  2013-02-27       Impact factor: 2.342

5.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis.

Authors:  Santiago Vilar; Rave Harpaz; Herbert S Chase; Stefano Costanzi; Raul Rabadan; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2011-09-21       Impact factor: 4.497

6.  Pattern Discovery from High-Order Drug-Drug Interaction Relations.

Authors:  Wen-Hao Chiang; Titus Schleyer; Li Shen; Lang Li; Xia Ning
Journal:  J Healthc Inform Res       Date:  2018-06-18

7.  Mechanism-based Pharmacovigilance over the Life Sciences Linked Open Data Cloud.

Authors:  Maulik R Kamdar; Mark A Musen
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

8.  Automatic identification and normalization of dosage forms in drug monographs.

Authors:  Jiao Li; Zhiyong Lu
Journal:  BMC Med Inform Decis Mak       Date:  2012-02-15       Impact factor: 2.796

9.  Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis.

Authors:  Santiago Vilar; Rave Harpaz; Lourdes Santana; Eugenio Uriarte; Carol Friedman
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

10.  Detection of drug-drug interactions by modeling interaction profile fingerprints.

Authors:  Santiago Vilar; Eugenio Uriarte; Lourdes Santana; Nicholas P Tatonetti; Carol Friedman
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.